PNPLA3 and metabolic dysfunction-associated steatohepatitis: Hereby, we demonstrated that in NASH livers PNPLA3 increased during fibrosis development, from mild (F1) to severe fibrosis (F4), along with the induction of the HSCs activation marker α‐SMA (Figures 1 and 2, Figure S1).